Schwedt TJ, Kuruppu DK, Dong Y, et al. - This study was undertaken to investigate the early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. Researchers randomized individuals with an episodic or chronic migraine from a 3-month, randomized, double-blind, placebo-controlled, phase 3b study who had two to four migraine preventive medication category failures in the past 10 years in a 1:1 ratio to placebo (N = 230) or galcanezumab 120 mg/month (240 mg loading dose; N = 232). They evaluated change from baseline in a number of monthly and weekly migraine headache days in this post-hoc analysis. They further assessed the proportion of patients with migraine headache days in the first week of treatment, and patients achieving ≥ 50%, ≥ 75%, and 100% response by month and week. This study’s findings demonstrated that Galcanezumab exhibited an early onset of effect beginning the day after treatment initiation in patients who had not previously benefited from migraine preventive treatments. A larger proportion of galcanezumab-treated patients achieved ≥50%, ≥75%, and 100% response at months 1–3 and at weeks 1–4 of month 1 vs placebo.